R&D News | pharmaphorum

News

ASCO: Conversational AI tackles missed colonoscopies

An artificial intelligence-based tool has shown impressive results in raising colorectal cancer screening rates in underserved populations.

News

ASCO: Gilead sifts lung cancer data for efficacy crumbs

Gilead Sciences’ bid to extend the uses of TROP2-directed Trodelvy into lung cancer currently rests on the results of its EVOKE-01 study, revealed for the first time at th

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Novartis cues up filings for remibrutinib in chronic hives

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – a

News

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.

News

First patient gets bowel cancer jab in NHS 'matchmaker' push

The first patient has received a personalised colorectal cancer vaccine, produced by BioNTech, as part of NHS England and Genomics England’s Cancer Vaccine Launch Pad (CVL

ASCO: Conversational AI tackles missed colonoscopies

ASCO: Gilead sifts lung cancer data for efficacy crumbs

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis cues up filings for remibrutinib in chronic hives

Gilead’s Trodelvy woes rise with failed bladder cancer trial

First patient gets bowel cancer jab in NHS 'matchmaker' push

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks